Fed’s Powell opens door to potential rate cuts at Jackson Hole
In recent transactions reported to the Securities and Exchange Commission, Verastem, Inc. (NASDAQ:VSTM) Chief Financial Officer Daniel Calkins sold shares of the company’s stock. On May 20, 2025, Calkins sold 11,143 shares at a price of $8.13 each, totaling $90,592. This sale was conducted to meet statutory withholding requirements related to the vesting of restricted stock units. The transaction comes amid strong momentum for Verastem shares, which have surged over 110% in the past six months, according to InvestingPro data.
Earlier, on May 16, 2025, Calkins acquired 38,850 shares of common stock at no cost. These shares were part of a performance-based restricted stock unit (RSU) award that vested following the FDA’s approval of a new drug application for Verastem’s combination therapy for low-grade serous ovarian cancer. Following these transactions, Calkins holds 114,055 shares of Verastem stock. With a current market capitalization of $438 million and analysts setting price targets between $13 and $20, InvestingPro analysis suggests the stock is currently trading below its Fair Value. Get access to 10+ additional exclusive ProTips and comprehensive analysis through the Pro Research Report.
In other recent news, Verastem Oncology has received early approval from the U.S. Food and Drug Administration for its combination therapy, avutometinib and defactinib, to treat recurrent KRAS mutant low-grade serous ovarian cancer. This approval came ahead of the scheduled Prescription Drug User Fee Act date, marking a significant milestone for the company. Jefferies responded by raising Verastem’s stock price target from $15 to $19 while maintaining a Buy rating, reflecting confidence in the therapy’s commercial potential. Meanwhile, Mizuho (NYSE:MFG) analysts have maintained an Outperform rating with an $8 price target, noting Verastem’s strengthened balance sheet and the potential for upcoming data catalysts.
Additionally, Verastem has secured $75 million in a private placement to support the launch of its newly approved therapy and further clinical research. The company plans to use these funds for development purposes, including the advancement of VS-7375, a KRAS G12D inhibitor. The FDA has cleared the Investigational New Drug application for VS-7375, allowing Verastem to initiate a Phase 1/2a study in mid-2025. This trial will focus on advanced KRAS G12D mutant solid tumors, including pancreatic and colorectal cancers. Verastem’s ongoing collaboration with GenFleet Therapeutics is expected to bolster its pipeline, with VS-7375 being a key focus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.